Cavanagh Jonathan, Patterson James, Pimlott Sally, Dewar Deborah, Eersels Jos, Dempsey Mary Frances, Wyper David
Division of Community Based Sciences, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom.
Biol Psychiatry. 2006 Feb 15;59(4):301-8. doi: 10.1016/j.biopsych.2005.06.029. Epub 2005 Sep 28.
Serotonin transporters (SERT) are a major target for antidepressant medication, although there have been limited in vivo studies of SERT availability in patients being treated with antidepressants. It is not known whether SERT availability differs in treatment-responsive and -nonresponsive patients receiving long-term treatment. In this study, we used single photon emission computed tomography (SPECT) to compare SERT residual availability in unipolar responders and nonresponders during long-term antidepressant treatment. Dopamine transporter (DAT) availability was also assessed in the same patients to examine the relationship between the two transporter systems.
Twenty-four medicated unipolar patients were recruited, of whom 11 were responders and 13 were nonresponders. All patients underwent SPECT with [123I] beta-carbomethoxy-3-beta-(4 iodophenyl)tropane. Brain SERT was measured in the brain stem and diencephalon, and DAT was measured in the striatum. Residual availability was calculated as a ratio of specific to nonspecific uptake, with the occipital region used as the nonspecific reference region.
There was no difference between responders and nonresponders in SERT availability. Dopamine transporter availability was similar in responders and nonresponders, and there was no association between SERT and DAT availability.
Serotonin transporter availability does not discriminate responders and nonresponders during long-term treatment with antidepressants.
血清素转运体（SERT）是抗抑郁药物的主要作用靶点，尽管关于接受抗抑郁药物治疗患者的SERT可用性的体内研究有限。目前尚不清楚在接受长期治疗的治疗反应者和无反应者中，SERT可用性是否存在差异。在本研究中，我们使用单光子发射计算机断层扫描（SPECT）来比较长期抗抑郁治疗期间单相抑郁症反应者和无反应者的SERT残余可用性。还对同一批患者的多巴胺转运体（DAT）可用性进行了评估，以研究这两种转运体系统之间的关系。
招募了24名接受药物治疗的单相抑郁症患者，其中11名是反应者，13名是无反应者。所有患者均接受了用[123I]β-羰甲氧基-3-β-（4-碘苯基）托烷进行的SPECT检查。在脑干和间脑测量脑SERT，在纹状体测量DAT。残余可用性通过特异性摄取与非特异性摄取的比值计算，枕叶区域用作非特异性参考区域。
反应者和无反应者在SERT可用性方面没有差异。反应者和无反应者的多巴胺转运体可用性相似，并且SERT和DAT可用性之间没有关联。
在抗抑郁药物长期治疗期间，血清素转运体可用性无法区分反应者和无反应者。
